Cancer vaccines in glioma: How to balance the challenges of small trials, efficiency, and potential adverse events

Journal of Clinical Oncology

Volumn 28, Issue 31, 2010, Pages 4670-4673

  Lowenstein, Pedro R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR V III; GANCICLOVIR; TEMOZOLOMIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII;

CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; EDITORIAL; GLIOBLASTOMA; GLIOMA; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; BRAIN TUMOR; EPIDEMIOLOGY; EUROPE; GENE EXPRESSION REGULATION; IMMUNOLOGY; MORTALITY; MULTICENTER STUDY; NOTE; PHASE 2 CLINICAL TRIAL; SURVIVAL; UNITED STATES;

BIAS (EPIDEMIOLOGY); BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS, PHASE II AS TOPIC; EUROPE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MULTICENTER STUDIES AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; UNITED STATES;

EID: 78149233272     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.1117     Document Type: Editorial

References (43)

1. Counsell CE, Grant R: Incidence studies of primary and secondary intracranial tumors: A systematic review of their methodology and results. J Neurooncol 37:241-250, 1998 (Pubitemid 28073696)
2. Pobereskin LH, Chadduck JB: Incidence of brain tumours in two English counties: A population based study. J Neurol Neurosurg Psychiatry 69:464-471, 2000
3. Wen PY, Black PM: Clinical presentation, evaluation, and preoperative preparation of the patient, in Berger MS, Wilson CB (eds): The Gliomas. Philadelphia, PA, W.B. Saunders, 1999, pp 328-336
4. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 359:492-507, 2008
5. Grossman SA, Ye X, Piantadosi S, et al: Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States. J Clin Oncol 27:87s, 2009 (suppl; abstr 2003)
6. Buckner JC: Central nervous system tumors: Central nervous system tumors track. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 29-June 2, 2009 (discussion)
7. Knisely JP, Baehring JM: A silver lining on the horizon for glioblastoma. Lancet Oncol 10:434-435, 2009
8. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
9. Sampson JH, Heimberger AB, Archer GE, et al: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722-4729, 2010
10. Määttä AM, Samaranayake H, Pikkarainen J, et al: Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 9:356-367, 2009
11. Immonen A, Vapalahti M, Tyynelä K, et al: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 10:967-972, 2004 (Pubitemid 39419922)
12. European Medicines Agency: Questions and answers on the recommendation for refusal of the marketing authorisation for Cerepro. http://www.ema.europa. eu/docs/en-GB/document-library/Summary-of-opinion---Initial-authorisation/human/ 000694/WC500017157.pdf
13. European Medicines Agency: Cerepro. http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/001103/wapp/Initial-authorisation/ human-wapp-000083.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d128&jsenabled=true
14. Mitchell P: Ark's gene therapy stumbles at the finish line. Nat Biotechnol 28:183-184, 2010
15. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
16. Lowenstein PR, Castro MG: Uncertainty in the translation of preclinical experiments to clinical trials: Why do most phase III clinical trials fail? Curr Gene Ther 9:368-374, 2009
17. Liau LM, Prins RM, Kiertscher SM, et al: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515-5525, 2005 (Pubitemid 41060828)
18. Yu JS, Liu G, Ying H, et al: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979, 2004 (Pubitemid 38924545)
19. Yu JS, Wheeler CJ, Zeltzer PM, et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847, 2001 (Pubitemid 32175145)
20. Liau LM, Jensen ER, Kremen TJ, et al: Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res 62:2287-2293, 2002 (Pubitemid 34411706)
21. De Vleeschouwer S, Fieuws S, Rutkowski S, et al: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098-3104, 2008
22. Wheeler CJ, Black KL, Liu G, et al: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955-5964, 2008
23. Heimberger AB, Crotty LE, Archer GE, et al: Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16-25, 2000 (Pubitemid 30058249)
24. Heimberger AB, Sampson JH: The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 9:1087-1098, 2009
25. Broder H, Anderson A, Kremen TJ, et al: MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. J Neurooncol 64:21-30, 2003 (Pubitemid 36992457)
26. Choi BD, Archer GE, Mitchell DA, et al: EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 19:713-723, 2009
27. Schmittling RJ, Archer GE, Mitchell DA, et al: Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 339:74-81, 2008
28. Heimberger AB, Sun W, Hussain SF, et al: Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neuro Oncol 10:98-103, 2008 (Pubitemid 351250906)
29. Yajima N, Yamanaka R, Mine T, et al: Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11:5900-5911, 2005 (Pubitemid 41170319)
30. Okada H, Lieberman FS, Walter KA, et al: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5:67, 2007
31. Ahmed R, Zha XM, Green SH, et al: Synaptic activity and F-actin coordinately regulate CaMKIIalpha localization to dendritic postsynaptic sites in developing hippocampal slices. Mol Cell Neurosci 31:37-51, 2006 (Pubitemid 43049900)
32. Sloan AE, Dansey R, Zamorano L, et al: Adoptive immunotherapy in patients with recurrent malignant glioma: Preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti- CD3-activated lymphocytes. Neurosurg Focus 9:e9, 2000
33. Kahlon KS, Brown C, Cooper LJ, et al: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64:9160-9166, 2004 (Pubitemid 39665531)
34. Bao L, Sun Q, Lucas KG: Rapid generation of CMV pp65-specific T cells for immunotherapy. J Immunother 30:557-561, 2007 (Pubitemid 46988089)
35. Bao L, Dunham K, Stamer M, et al: Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14:1156-1162, 2008
36. Dillman RO, Duma CM, Schiltz PM, et al: Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27:398-404, 2004 (Pubitemid 39121929)
37. Pluhar GE, Grogan PT, Seiler C, et al: Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 28:3371-3378, 2010
38. Eck SL, Alavi JB, Judy K, et al: Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferonbeta (H5.010CMVhIFN-beta): A phase I trial. Hum Gene Ther 12:97-113, 2001 (Pubitemid 32044471)
39. Chiocca EA, Smith KM, McKinney B, et al: A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16:618-626, 2008 (Pubitemid 351315003)
40. Lemere CA, Masliah E: Can Alzheimer disease be prevented by amyloidbeta immunotherapy? Nat Rev Neurol 6:108-119
41. Gan HK, Kaye AH, Luwor RB: The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16:748-754, 2009
42. Rosell R, Taron M, Reguart N, et al: Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 12:7222-7231, 2006 (Pubitemid 46095393)
43. Ziliak ST, McCloskey, DN: The Cult of Statistical Significance: How the Standard Error Costs Us Jobs, Justice, and Lives. Ann Arbor, MI, University of Michigan Press, 2008